| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2012 | US20120015036 Process For The Manufacture Of A Pharmaceutical Product |
| 01/19/2012 | US20120015035 Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists |
| 01/19/2012 | US20120015033 Antisense compositions and methods of making and using same |
| 01/19/2012 | US20120015032 Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
| 01/19/2012 | US20120015031 Novel gastro-retentive dosage forms |
| 01/19/2012 | US20120015030 Modified release formulations containing drug-ion exchange resin complexes |
| 01/19/2012 | US20120015029 Direct compression formulation and process |
| 01/19/2012 | US20120015028 Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof |
| 01/19/2012 | US20120015027 F, G, H, I and K Crystal Forms of Imatinib Mesylate |
| 01/19/2012 | US20120015026 Pharmaceutical composition containing a drug and sirna |
| 01/19/2012 | US20120015025 Cholestanol derivative for combined use |
| 01/19/2012 | US20120015023 Treatment of tumors prostate with arsonoliposomes |
| 01/19/2012 | US20120015020 Biodegradable drug or other active delivery system |
| 01/19/2012 | US20120015019 Drug Coated Balloon With In-Situ Formed Drug Containing Microspheres |
| 01/19/2012 | US20120015014 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 01/19/2012 | US20120015007 Abuse resistant formula |
| 01/19/2012 | US20120015005 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
| 01/19/2012 | US20120015001 Methods of treating thyroid eye disease |
| 01/19/2012 | US20120014997 Aryl sulfonamides |
| 01/19/2012 | US20120014990 Vaccination methods |
| 01/19/2012 | US20120014989 PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS |
| 01/19/2012 | US20120014981 Avirulent, immunogenic flavivirus chimeras |
| 01/19/2012 | US20120014974 Methods of modulating cell death based on the bit1/aes regulatory pathway |
| 01/19/2012 | US20120014965 Compositions and methods of treating tumors |
| 01/19/2012 | US20120014964 Alpha synuclein toxicity |
| 01/19/2012 | US20120014962 Method of inhibiting fibrogenesis and treating fibrotic disease |
| 01/19/2012 | US20120014949 Serum Biomarkers For Early Detection Of Acute Cellular Rejection |
| 01/19/2012 | US20120014947 Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system |
| 01/19/2012 | US20120014934 Enhanced Natural Colors |
| 01/19/2012 | US20120014920 Annexin and its use to treat inflammatory disorders |
| 01/19/2012 | US20120014918 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors |
| 01/19/2012 | US20120014917 Methods of treating hiv patients with anti-fibrotics |
| 01/19/2012 | US20120014916 Polyalkylene polymer compounds and uses thereof |
| 01/19/2012 | US20120014915 Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders |
| 01/19/2012 | US20120014914 Inhibitors of serine proteases, particularly hcv ns3-ns4a proteases |
| 01/19/2012 | US20120014913 Process for preparing antiviral compounds |
| 01/19/2012 | US20120014912 Palatable pharmaceutical composition |
| 01/19/2012 | US20120014911 Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| 01/19/2012 | US20120014908 Terminally-functionalized conjugates and uses thereof |
| 01/19/2012 | US20120014907 Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases |
| 01/19/2012 | US20120014906 Organic compounds |
| 01/19/2012 | US20120014905 Conugated proteins and peptides |
| 01/19/2012 | US20120014904 Vascular delivery systems |
| 01/19/2012 | US20120014899 Cosmetic method using a composition containing siloxane resins and fillers |
| 01/19/2012 | US20120014893 Antimycotic pharmaceutical composition |
| 01/19/2012 | US20120014889 Methods for making 1,3-dihydroxyacetone (dha) from glycerol |
| 01/19/2012 | US20120014884 Menthol-derivative compounds and use thereof as oral and systemic active agents |
| 01/19/2012 | US20120014883 Compositions Comprising Derivatives Of Essential Oil Compounds And Use In Personal Care Products |
| 01/19/2012 | US20120014877 COMPOSITIONS AND METHODS TO TREAT CANCER WITH CpG RICH DNA AND CUPREDOXINS |
| 01/19/2012 | US20120014875 Nucleic acid aptamers |
| 01/19/2012 | US20120014874 Photosensitizer-metal nanoparticle charge complex and composition containing the complex for photodynamic therapy or diagnosis |
| 01/19/2012 | US20120014871 Ovarian Cancer Methylome |
| 01/19/2012 | US20120012499 Tablet formulation |
| 01/19/2012 | US20120012123 Compositions, articles and methods for preventing or reducing tobacco-associated damage |
| 01/19/2012 | CA2807354A1 P2x4 receptor antagonist |
| 01/19/2012 | CA2807318A1 Novel tetrahydropyrazolo[3,4-b]azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| 01/19/2012 | CA2805748A1 Process for preparing antiviral compounds |
| 01/19/2012 | CA2805724A1 Organic compounds |
| 01/19/2012 | CA2805700A1 Pharmaceutical compositions |
| 01/19/2012 | CA2805669A1 Therapeutically active compositions and their methods of use |
| 01/19/2012 | CA2805645A1 C-met modulator pharmaceutical compositions |
| 01/19/2012 | CA2805631A1 Drug delivery medical device |
| 01/19/2012 | CA2805608A1 Substituted imidazoquinoline derivatives as kinase inhibitors |
| 01/19/2012 | CA2805590A1 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 01/19/2012 | CA2805356A1 Composition for the treatment of superficial lesions |
| 01/19/2012 | CA2805318A1 Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| 01/19/2012 | CA2805294A1 Compounds for the reduction of beta-amyloid production |
| 01/19/2012 | CA2805222A1 Method and formulations for treating sialic acid deficiencies |
| 01/19/2012 | CA2805219A1 Pyrazole compound |
| 01/19/2012 | CA2805171A1 Parenteral formulations of elacytarabine derivatives |
| 01/19/2012 | CA2805148A1 Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors |
| 01/19/2012 | CA2805136A1 New compounds for treating cancer and other diseases |
| 01/19/2012 | CA2805110A1 Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists |
| 01/19/2012 | CA2805015A1 Bicyclic pyrimidines |
| 01/19/2012 | CA2804970A1 Spirocyclic compounds |
| 01/19/2012 | CA2804962A1 Patch for treating skin deseases and alleviating symptoms of skin diseases involving education of blood proteins |
| 01/19/2012 | CA2804845A1 Substituted imidazo[1,2-a]pyrimidines and -pyridines |
| 01/19/2012 | CA2804823A1 Synthesis of 2'-deoxy-2'-[18f]fluoro-5-methyl-1-b-d-arabinofuranosyluracil (18f-fmau) |
| 01/19/2012 | CA2804794A1 Bovine milk oligosaccharides |
| 01/19/2012 | CA2804779A1 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them |
| 01/19/2012 | CA2804744A1 Ip receptor agonist heterocyclic compounds |
| 01/19/2012 | CA2804716A1 Chemical compounds |
| 01/19/2012 | CA2804640A1 Aldose reductase inhibitors and uses thereof |
| 01/19/2012 | CA2804635A1 Formulations of rifaximin and uses thereof |
| 01/19/2012 | CA2804351A1 Chemical compounds |
| 01/19/2012 | CA2804162A1 New crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl}-1-azetidinesulfonamide |
| 01/19/2012 | CA2803999A1 Anti-angiogenic composition containing macrolactin a and a derivative thereof as active ingredients |
| 01/19/2012 | CA2803675A1 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 01/19/2012 | CA2803471A1 Aqueous composition comprising bromhexine |
| 01/19/2012 | CA2803322A1 Fermented soya based mixture comprising isoflavones-aglycones, equol and lunasin, process for the preparation thereof and related uses in food, medical and cosmetic fields |
| 01/19/2012 | CA2803242A1 Backing having three-layer structure and aqueous patch using the backing |
| 01/19/2012 | CA2803187A1 Treatment of lung infections by administration of tobramycin by aerolisation |
| 01/19/2012 | CA2802808A1 Purine compounds selective for pi3k p110 delta, and methods of use |
| 01/19/2012 | CA2802641A1 Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| 01/19/2012 | CA2802528A1 New azacyclic compounds |
| 01/19/2012 | CA2801032A1 N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| 01/19/2012 | CA2800971A1 Chemical compounds |
| 01/19/2012 | CA2771928A1 Oxazine derivatives and their use in the treatment of neurological disorders |
| 01/19/2012 | CA2768199A1 (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| 01/18/2012 | EP2407786A1 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer |